Side Liu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
-
- RNA modifications and cancer
- RNA Research and Splicing
- Ubiquitin and proteasome pathways
- Circular RNAs in diseases
- Epigenetics and DNA Methylation
Papers in
-
- Cancer-related molecular mechanisms research 10
- MicroRNA in disease regulation 4
-
- RNA modifications and cancer 6
- RNA Research and Splicing 4
- Ubiquitin and proteasome pathways 3
- Histone Deacetylase Inhibitors Research 2
- Co-authors
- Jide WangXiaosheng WuWeimei TangAimin LiXiang LiJiaying LiWeiyu DaiXinke Wang
- Journals
- Cell Death and Disease (3 papers)Oncogene (3 papers)Nature Communications (2 papers)Frontiers in Oncology (2 papers)Aging (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Side Liu
21 papers receiving 740 citations
Peers
Comparison fields: 5 of 70
- Cancer Research 316
- Molecular Biology 510
- Oncology 158
- Immunology 81
- Molecular Medicine 19
Countries citing papers authored by Side Liu
This map shows the geographic impact of Side Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Side Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Side Liu more than expected).
Fields of papers citing papers by Side Liu
This network shows the impact of papers produced by Side Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Side Liu. The network helps show where Side Liu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Side Liu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 3 | |
| 3 | 2023 | 8 | |
| 4 | 2023 | 12 | |
| 5 | 2023 | 38 | |
| 6 | 2022 | 37 | |
| 7 | 2022 | 79 | |
| 8 | 2021 | 27 | |
| 9 | 2021 | 25 | |
| 10 | 2021 | 33 | |
| 11 | 2021 | 21 | |
| 12 | 2020 | 68 | |
| 13 | 2020 | 45 | |
| 14 | 2020 | 22 | |
| 15 | 2020 | 6 | |
| 16 | 2019 | 47 | |
| 17 | 2019 | 99 | |
| 18 | 2018 | 44 | |
| 19 | 2018 | 16 | |
| 20 | 2017 | 12 |
About Side Liu
Side Liu is a scholar working on Cancer Research, Molecular Biology, Oncology, Gastroenterology and Pulmonary and Respiratory Medicine, having authored 22 papers that have together received 744 indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (10 papers), RNA modifications and cancer (6 papers), MicroRNA in disease regulation (4 papers), RNA Research and Splicing (4 papers), Cancer Cells and Metastasis (3 papers), Ubiquitin and proteasome pathways (3 papers), Ferroptosis and cancer prognosis (2 papers) and Histone Deacetylase Inhibitors Research (2 papers). The work is most often cited by research in Cancer Research (316 citations), Molecular Biology (510 citations), Oncology (158 citations), Immunology (81 citations) and Molecular Medicine (19 citations). Side Liu has collaborated with scholars based in China and United States. Frequent co-authors include Jide Wang, Xiaosheng Wu, Weimei Tang, Aimin Li, Xiang Li, Aimin Li, Jiaying Li, Weiyu Dai, Xinke Wang and Yizhi Xiao. Their work appears in journals such as Cell Death and Disease, Oncogene, Nature Communications, Frontiers in Oncology and Aging.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.